For optometrists and ophthalmologists
Hospital-grade care, inside your consulting room.
Revolux integrates active dry AMD intervention into the workflows you already run, turning an unmet patient need into a scalable, high-value clinical service.
Beyond generic light therapy
Bespoke treatment protocols optimise retinal stimulation beyond generic or fixed photobiomodulation.
Continuous revenue
Repeatable treatment cycles generate sustainable recurring revenue that scales linearly with patient volume.
Integrated workflows
Therapy slots into existing clinical workflows without dedicated space or fixed infrastructure.
Intelligent insights
Integrated software simplifies clinical reporting and supports decisions, reducing administrative burden.
Consistent delivery
Continuous care models replace passive management, keeping patients engaged with therapy over time.
No upfront cost
A low-friction subscription model eliminates high upfront costs, so the service is profitable from the start.
In practice
The clinical pathway
Five steps, all inside the practice. The device, the software and the protocol are designed around a standard appointment.
- 01
Identify
Adults aged 50 and over with early or intermediate dry AMD, found during routine examination or imaging.
- 02
Screen
Eligibility is confirmed and contraindications are managed by the supervising clinician before any treatment.
- 03
Treat
Nine five-minute binocular sessions over three weeks, three sessions a week, in a standard consulting room.
- 04
Report
Every session is logged. Clinician-ready reports and patient-friendly summaries are generated automatically.
- 05
Continue
Ongoing care replaces passive monitoring, with repeatable cycles delivered within a managed pathway.
The course
Nine sessions over three weeks.
Three sessions a week, five minutes each. The schedule is designed to maximise cellular response while fitting into manageable clinic blocks.
0minutes of treatment
0/9sessions delivered
- Week 1
- Week 2
- Week 3
3 weeks of 3 sessions, 5 minutes each: 9 sessions and 45 minutes in total.
Forty-five minutes of treatment in total, across three weeks of ordinary appointments.
Practice economics
A low break-even point.
Revolux is offered on subscription with no upfront cost. Just one patient every three months covers the device subscription, which makes it a low-risk addition to a practice.
Monthly profit
£1,600
Annual profit
£19,200
Monthly profit by caseload
- 1 a month
- £700
- 2 a month
- £1,600
- 3 a month
- £2,500
Illustrative figures based on BioPhotonix's published examples. Actual results depend on your pricing, case mix and local costs.
Slider at 11 percent.You ask, we answer
Frequently asked questions
Answers to the questions optometrists and ophthalmologists ask most about Revolux and what it means for their patients.
Revolux is indicated for adult patients aged 50 and over diagnosed with early or intermediate dry AMD. It allows clinicians to offer active intervention during the years where patients were previously told to simply watch and wait.
Register your interest
See how Revolux fits your practice.
We are working with a small group of clinics ahead of pilot clinical evaluation. Tell us about your practice and we will be in touch.